What is ACRV's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.08B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ACRV?

P/E (TTM) is n/a and 52-week range is $1.27 to $3.56 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ACRV figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ACRV?

The company profile lists net income (TTM) near $-81M, EPS (TTM) near $-1.88 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Acrivon Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Watertown, Massachusetts, US, 42.8M shares outstanding, ISIN US0048901096 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Acrivon Therapeutics Inc

$ACRV

Health Care · Biotechnology

IR Run Scenarios

$1.91

+2.14%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2022-11-15. The company uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Employees

Website

acrivon.com/

IPO

2022-11-15

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)